ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by BidaskClub

ProQR Therapeutics (NASDAQ:PRQR) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday, BidAskClub reports.

A number of other research firms have also recently weighed in on PRQR. Citigroup raised their price target on ProQR Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. ValuEngine upgraded ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 28th. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of ProQR Therapeutics in a research note on Friday, October 11th. Finally, Zacks Investment Research cut ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. ProQR Therapeutics presently has a consensus rating of “Buy” and an average price target of $27.00.

ProQR Therapeutics stock traded down $0.03 during midday trading on Tuesday, reaching $8.29. The company’s stock had a trading volume of 77,645 shares, compared to its average volume of 233,721. ProQR Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $16.99. The company has a quick ratio of 7.01, a current ratio of 7.01 and a debt-to-equity ratio of 0.18. The company has a market cap of $413.72 million, a P/E ratio of -6.43 and a beta of 0.40. The business has a 50-day simple moving average of $9.13 and a 200-day simple moving average of $8.01.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). As a group, equities analysts forecast that ProQR Therapeutics will post -1.56 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its holdings in shares of ProQR Therapeutics by 223.5% in the third quarter. Millennium Management LLC now owns 222,579 shares of the biopharmaceutical company’s stock valued at $1,282,000 after buying an additional 402,779 shares during the last quarter. State Street Corp increased its stake in shares of ProQR Therapeutics by 13.4% during the third quarter. State Street Corp now owns 123,870 shares of the biopharmaceutical company’s stock worth $713,000 after acquiring an additional 14,610 shares during the period. International Biotechnology Trust PLC acquired a new position in shares of ProQR Therapeutics during the second quarter worth about $511,000. Jane Street Group LLC purchased a new position in ProQR Therapeutics during the second quarter worth about $92,000. Finally, Tower Research Capital LLC TRC purchased a new position in ProQR Therapeutics during the second quarter worth about $79,000. 43.89% of the stock is currently owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

See Also: Percentage Decliners

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.